Nonadherence to imatinib during an economic downturn

New England Journal of Medicine

Volumn 363, Issue 6, 2010, Pages 596-598

  Kelley, Robin K ^a   Venook, Alan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG COST; DRUG INDUSTRY; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; LETTER; METASTASIS; PATIENT COMPLIANCE; PELVIS TUMOR; PERITONEUM CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 77955287514     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1004656     Document Type: Letter

References (5)

1. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5.
2. Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009;15:5910-6.
3. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
4. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96. (Pubitemid 46849189)
5. Halpern R, Barghout V, Mody-Patel N, Williams D. Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate. J Clin Oncol 2008;26:Suppl:5S. abstract.